anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided are adoptive cell therapy methods involving the administration of doses of cells for treating B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods involve prior administration of a lymphodepleting therapy, such as prior administration of fluradibine and/or another lymphodepleting chemotherapeutic agent, for example cyclophosphamide. In some embodiments, features of the methods include an increase in complete remission, overall survival and/or progression free survival of subjects treated in accord with the provided methods.
Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
The invention relates to quality inspection filed of traditional Chinese medicines, discloses a quality inspection method of a medical combination used for treating gynecological hysteromyoma. The inspection method comprises the steps of identification, inspection, determination of extract and content, etc. of the drugs for treating gynecological hysteromyoma. By adopting the thin layer chromatography, the inspection method of the invention realizes identification of leech, zedoary, frangula-emodin, emodin monomethylether, osthole, peach kernel, paeoniflorin and baicalin, and accurate determination of content of dracorhodin, an active component of monarch drug resina draconis, by adopting the high performance liquid chromatography. Each granule of the medical combination contains resina draconis no less than 0.50mg, counted by dracorhodin C17H14O3. The quality inspection method of the invention has simple, convenient, accurate and advanced operation; linear relation, repeatability, precision, stability and recovery are all good, and the method can effectively control the quality of products and guarantee the curative effect of products.
This is a children's study. Patients experience significant postoperative pain, activity limitation and sometimes other significant postoperative complications. We are going to compare the effects of closing the tonsil wound versus non-closure. A daily journal will be kept (by the patient's parent or legal guardian)to log in measures of morbidity. Postoperative telephone calls will be made and scripted questions will be asked regarding any tonsillar hemorrhage requiring medical re-evaluation, and dehydration requiring medical re-evaluation. The patients will also be examined in the clinic at 10-14 days postoperatively to determine if the fossa remained closed or dehisced.
Slow-release beta-alanine (Natural Alternatives International, Carlsbad, CA, USA). Dose: 4.8 grams per day for 3-months (potential total intake of 432 g beta-alanine). The daily intake will be split into four doses of 2 x 600 mg. Participants will be instructed to consume each dose alongside their main daily meals (e.g., breakfast, lunch, and dinner) and before bed.
The invention discloses an application of pigeonpea extract and an active ingredient pinosylvin monomethyl ether thereof in preparation of an aspergillus flavus inhibition product. The research shows that the pigeonpea extract has obvious aspergillus flavus resisting activity. Meanwhile, the active ingredient pinosylvin monomethyl ether in the cajan leaves can inhibit the growth of aspergillus flavus, the germination of spores and the accumulation of aflatoxins, and inhibit bacteria IC  50  Is 0.26mg/mL. Can completely inhibit the growth of Aspergillus flavus at the concentration of 0.5mg/mL, and has negligible hemolytic activity. Further mechanism studies have found that PMEs are able to target cell membranes, resulting in extravasation of the contents. In view of the strong anti-aspergillus flavus activity of the pigeonpea extract and the pinosylvin monomethyl ether, the method has good development and application prospects in the preparation of anti-aspergillus flavus products.
PURPOSE:To provide the titled garlic liquid to be applied to the diseased part of the skin, e.g. sore, tinea, athlete's foot, bite, etc., by aging deodorized garlic in alcohol and mixing the liquid with other drug. CONSTITUTION:Deodorized garlic is dried in the sun for about 15 days. 1 kg of the deodeorized and dried garlic is aged in 5.4 liters of alcohol for >=6 months in dark place to obtain stock liquid of deodorized garlic. The objective deodorized garlic liquid for application can be produced by adding 60 ml of the garlic liquid, 3-4 ml of round UP, 4 ml of undecylene and 3-4 g of salicylic acid to 100 liters of the base liquid for application and thoroughly mixing the mixture. The liquid may contain a releasing agent, a disinfectant, etc. Garlic liquid is effective to promote the blood flow and heat and sterilize the diseased part and the round UP kills pathogens. Undecylenoic acid eliminates mold, and salicylic acid exhibits keratolytic action of the diseased skin to promote the tanscutaneous absorption of the drug components.
This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from solid tumor malignancies. Study objectives will include safety (1a/1b), pharmacokinetics (PK) and pharmacodynamics (PD) of IT-DFO (1a), and preliminary anti-tumoral efficacy in patients with LM solid tumor malignancies (1b).
High intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio. For isometric wall squat, each training session will be composed of 4 × 2-min bouts of IWS followed by 2-min rest periods At the end of each bout, participants will be given an RPE score. This score will then be compared to a target RPE value and zone for each bout, There will be total 15 sessions thrice a week for 5 weeks.
1411661 Candida antiserum AJINOMOTO CO Inc 27 March 1973 [4 July 1972] 14778/73 Heading A5B An anti-serum for serological identification of pathogenic species of Candida is prepared by (a) separating cell wall mannan from a yeast having at least one antigen factor in common with Candida albicans, (b) bonding said mannan to a carrier protein alien to yeasts to produce a haptan-carrier complex, said mannan constituting the hapten in said complex, (c) parenterally administering said complex to a warm-blooded animal in an amount sufficient to induce an anti-serum which contains antibodies specific to said yeast in the blood of the animal and (d) harvesting said blood. The yeast may be C. albicans, C. tropicalis, C. pseudotropicalis, Kluyveromyces fragilis, C. guilliermondi, C. parakrusei, Metschnikowia pulcherrima, Pichia fermentans or Toruopsis glabrata.The protein may be bovine gamma-globulin. The mannan may be bonded to the protein by reaction with a polychlorinated triazine or with bromoacetyl bromide. The hapten-protein complex may be administered intravenously to a rabbit. The fibrinogen and corpuscles may be removed from the harvested blood to produce the antiserum. Some of the antibody factors may be removed from the antiserum by treatment with a yeast.
This randomized clinical trial was conducted in Shahid Labbafi nejad hospital. 35 renal transplanted patients enter the study and randomized to one of two groups: everolimus or control (Sandimmun or tacrolimus). However, 34 patients completed study (17 patients in each group). The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose and in control group was standard dose of Sandimmun or tacrolimus plus cellcept. All patients gave Antithymocyte Glubolin and prednisolone. In addition, they gave CMV prophylaxis until 3 months. Kidney biopsies were done for raise of creatinine or protocol biopsy at 6 month after transplantation. Demographic, renal disease and transplantation characteristics, CMV and BK virus status, rejection, and routine laboratory tests recorded during study period and compared between two groups.
This a phase 1, single arm, non-randomized trial of tazemetostat in combination with venetoclax in participants with two types of relapsed/refractory non-Hodgkin lymphoma. The purpose of this study is to evaluate the safety of the combination of tazemetostat and venetoclax in patients with relapsed/refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). This trial will be conducted in two parts. Part one will be a single-arm, open-label sequential dose escalation (3+3) of venetoclax in combination with a fixed dose of tazemetostat (800mg BID) to determine the maximum tolerated dose (MTD) of venetoclax. In part two, two expansion cohorts (R/R DLBCL and R/R FL) will be enrolled to further characterize the safety and tolerability of the combination, and to estimate the preliminary efficacy. Up to 18 participants will be enrolled in part 1 and 20 participants will be enrolled in part 2.
Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
Preclinical studies in mice and rats based on three microinfusions (12 hours apart) of specifically designed and synthesized adenosine A1 receptor antisense oligonucleotide with the sequence: (A1Antisense: 5'-GGCCGAGATGGAGGGCGGCAT-3' (SEQ ID NO: 1)) and as a control, a mismatched antisense nucleotide with a sequence: (A1Sense: 5'-ATGCCGCCCTCCATCTCGGCC-3' (SEQ ID NO: 1)) established that the "functional knock out" of A1 receptors protected the animals from the well known motor incoordination due to alcohol or  DELTA 9-tetrahydrocarnabinol(THC: the major psychoactive component of marijuana intake). The motor coordination in animals was evaluated by the mouse/rat rotorod treadmill. The antisense was microinfused in mouse cerebellum and in the rat motor cortex whereas ethanol was always administered systemically. However, unlike ethanol, the  DELTA 9-THC was microinfused into the mouse cerebellum following the cerebellar pretreatment with the antisense. In addition to protection of alcohol or the  DELTA 9-THC-induced motor incoordination the above antisense molecule should block all functions expressed via adenosine A1 receptor, such as hypnosis and general CNS intoxication, thereby, further expanding the clinical applications of this oligonucleotide. This antisense may also be useful in treating asthma and anginal chest pains.
Thyroid cancer (TC) is the most frequent malignancy of the endocrine system. Apatinib, as an anti-angiogenic agent, has been applied in the therapy of several cancers. However, the function and mechanism of Apatinib in TC have not been clearly elucidated. After processing with Apatinib alone or combined PKM2 overexpression plasmids, cell proliferation, migration, and invasion were analyzed by EdU staining, CCK-8, wound healing, and Transwell. Meanwhile. HUVECs were incubated with the conditioned medium prepared from cell culture medium, and tube formation and VEGFR2 expression in HUVECs were examined using tube formation and immunofluorescence (IF) assays. Besides, we established a nude mouse xenograft model by lentivirus-mediated PKM2 shRNAs, and tested the growth of tumors; the pathological structure was analyzed with H&E staining. And the expressions of N-cadherin, Vimentin, E-cadherin, PKM2, VEGFA, VEGFR2, and Ki67 were determined by immunohistochemistry or Western blot. Apatinib could prominently suppress proliferation, migration, invasion, and HUVEC tube formation in SW579 and TPC-1 cells. Besides, we discovered that Apatinib had a significant inhibitory role on the expression of pyruvate kinase M2 (PKM2) in TC cells. And PKM2 overexpression also could notably reverse Apatinib-mediated inhibition of TC progression. Moreover, PKM2 shRNAs were applied to TC xenografts, resulting in significant reduction in tumor volume and suppression of angiogenesis-related protein expression. In summary, Apatinib has a regulatory role in TC progression, and Apatinib can block cancer cell angiogenesis by downregulating PKM2. This will provide a theoretical basis for therapy of TC.
Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.
A dry powder inhalation device includes in certain embodiments a spin chamber and a cartridge for holding multiple capsules. The capsules contain a dry powder that in certain embodiments includes methacholine. In certain embodiments, an adjustable limiting mechanism is configured to limit inhaled volume through the second passageway. In certain embodiments, the cartridge moves linearly or radially though a portion of the device. In certain embodiments, capsules in the cartridge align with a port in the spin chamber to load into the spin chamber. User inhalation on a mouthpiece of the device generates a vortical airflow and causes the capsules to spin within the chamber, releasing a portion of the dry powder for inhalation. In certain embodiments, the device is used for an inhalation diagnostic challenge. The inhalation diagnostic challenge can be automated, using a graphical user interface, an imaging system, user feedback mechanisms, and electromechanical components within the device for automating device operation.
With rising life expectancy, women are expected to spend a third of their lives in the postmenopausal stage. Consequently, focusing research on postmenopausal women is considered crucial. This study was conducted to determine the effects of kinesiotaping (KT) and sham KT applied with exercise program on clinical parameters such as pain, sleep, and quality of life in postmenopausal women with chronic low back pain. A randomized controlled experimental design, characteristic of quantitative research, was utilized. The subjects consisted of 60 postmenopausal women. The Visual Analog Scale (VAS), Roland Morris Disability Questionnaire (RMDQ) and Pittsburgh Sleep Quality Index (PSQI) were used as data collection tools.
The invention provides a zinc gluconate oral solution and a preparation method thereof. Every 1000mL of oral solution is prepared from 2.5-3.5g of zinc gluconate, 100-200g of white granulated sugar, 0.1-1.3g of casein phosphopeptides and 0.10-0.30mL of essence. The preparation method comprises the following steps: by using the above components as raw and auxiliary materials, dissolving; preparing; filtering; filling; carrying out flowing steam sterilization; packaging and the like. Compared with the conventional formula, in a novel formula, the casein phosphopeptide is added as an absorption promoter to effectively promote the human body to absorb and utilize zinc, so that absorption utilization ratio of zinc is improved. Meanwhile, the oral solution dosage is adopted, so that the bioavailability is further improved. The casein phosphopeptide is free from safety problem and easily accepted by people and is good in stability. The food with the casein phosphopeptide maintains the original flavor and taste. Compared with the conventional process, the novel process is used for effectively improving the clarity and stability of the finished product.
Reports in the literature indicate treatment of RLS with dopaminergic medications can result in recurrence of symptoms in the early morning hours, referred to as rebound. Augmentation has also been described during therapy for RLS. Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. Rebound refers to new onset of symptoms in the early morning hours. Augmentation and/or early-morning rebound have been observed in a postmarketing trial. If augmentation or early-morning rebound occurs, the use of ropinirole hydrochloride should be reviewed and dosage adjustment or discontinuation of treatment should be considered.
The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Human papillomavirus (HPV) is a common viral infection among men and women. Individuals with HPV are at risk for anal dysplasia, a condition that may lead to anal cancer. It has been observed that HIV progresses more rapidly in individuals coinfected with HPV and HIV, compared to people with either disease alone. Studies that have investigated the effect of highly active antiretroviral therapy (HAART) on the progression of anal dysplasia have been contradictory and inconclusive. The role of CD4 count and HIV suppression and their contributions to the progression of anal disease needs to be determined. This trial is a substudy of a study of management of antiretroviral therapy (SMART). In the SMART study, patients will participate in one of two strategies: a drug conservation (DC) strategy and a viral suppression (VS) strategy. Participants in the DC group will stop or defer HAART, then receive episodic HAART treatment for the minimum time needed to maintain a CD4 cell count of at least 250 cells/mm3. Participants in the VS group will receive HAART to maintain a viral load as low as possible, regardless of CD4 count. This study will compare the times to development of high-grade anal dysplasia or anal cancer in participants who are currently enrolled in the SMART study.

Patients will participate in this substudy and the main SMART study at the same time. At the baseline visit, participants will undergo an anal swab; some female participants will have a cervical swab as well. Participants will provide a detailed sexual history including sexually transmitted infections, a history of anal-related conditions, and a history of alcohol and recreational drug use. These procedures will be repeated at each annual follow-up visit. Some participants may undergo additional anal cytology and high-resolution anoscopy with biopsy. Participants will be followed until they develop high-grade anal dysplasia or anal cancer or when the SMART study closes, whichever comes first.
Dyslipidaemia is a common chronic kidney disease (CKD) and contributes to excessively elevated cardiovascular mortality. The pathophysiology is complex and modified by comorbidities like the presence/absence of proteinuria, diabetes mellitus or drug treatment. This paper provides an overview of currently available treatment options. We focused on individuals with CKD and excluded those on renal replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplantation). The use of statins is safe and recommended in most patients, but guidelines vary with respect to low-density lipoprotein (LDL) cholesterol goals. While no dedicated primary or secondary prevention studies are available for pro-protein convertase subtilisin/kexin type 9 inhibitors, secondary analyses of large outcome trials reveal no effect modification on endpoints by the presence of CKD. Similar data have been shown for bempedoic acid, but no definite conclusion can be drawn with respect to efficacy and safety. No outcome trials are available for inclisiran while the cholesterol lowering effects seem to be unaffected by CKD. Finally, the value of fibrates and icosapent ethyl in CKD is unclear. Lipid abnormalities contribute to the massive cardiovascular disease burden in CKD. Lowering of LDL cholesterol with statins (and most likely PCSK9 inhibitors) reduces the event rate and thus statin therapy should be initiated in almost all individuals. Other interventions (bempedoic acid, inclisiran, fibrates, or icosapent ethyl) currently need a case-by-case decision before prescription.
Most activities of everyday life require the use of both hands in a coordinated manner. Motor disorders related to cerebral palsy lead to activity limitations due to motor function disturbances. It has already been shown that intensive bimanual intervention can improve arm movement, but its impact on the spontaneous use of the most affected arm in everyday life remains to be established. This project aims to understand the impacts of intensive bimanual therapy on the motor functions of both arms (working together or in isolation) as well as on the spontaneous use of the most affected limb. Predictive value of neuroimaging variables will also be assessed. Thirty children living with cerebral palsy will be recruited over a 5-year period. The intervention consists of a day camp, where a small group of participants will be stimulated (one worker per child) to do activities using both hands 6 hours/day for 10 days. There will be three periods of evaluation (pre-intervention, post-intervention and 6-month follow-up). These evaluation periods consist of neuroimaging assessment, clinical evaluation, robotic evaluation and movement evaluation using inertial control units. The use of more accurate measurements of sensorimotor arm functions using robotic systems will clarify the relationship between measurements of brain function and clinical improvements, to better understand the significant variability observed in response to interventions.
The invention discloses a Chinese medicine pill for treating esophageal cancer and a process technology. By mainly aiming at the disadvantages of modern technologies, treatment focusing on relieving both secondary and primary symptoms, strengthening the body resistance and eliminating evil and fixed-point targeted medicine use are adopted so that not only the immunity of the organism is improved, but the treatment effect for suppressing growth of cancer cells is also realized. The Chinese medicine pill for treating esophageal cancer is characterized by consisting of rhizoma paridis, blackberrylily rhizome, American ginseng, radix astragali, poria cocos, purple sal ammoniac, podophyllum hexandrum, ruddle, bear bile, calculus bovis factitius, menthol crystal, barium sulfate, colla asini and the like. Two double-layer pills for fixed-point targeted treatment are produced by applying a layered pill production technology and a clinical mechanics principle. The first pills are generally taken in morning and mainly used for opening the esophagus to guarantee food nutrition intake. The second pills are generally taken in evening to be remained at a lesion position and mainly used for killing cancer cells directionally to play the role in suppressing tumor growth and relieving pain as well as swelling.